What inspires us to be innovators and disruptors? It’s the 40 million people living with HIV around the world. Our mission is to leave no person living with HIV behind and that’s why we won't stop innovating.
HIV
We are world leaders in next-generation HIV treatment and prevention, through ViiV Healthcare which we majority own. We have an industry-leading pipeline, driven by patient insights.
World leaders in next-generation HIV innovation
HIV remains one of the world’s biggest health epidemics, with 1.3 million new diagnoses annually, and more than 40 million people living with HIV. There is not yet a cure for HIV; however, 40 years of innovation has transformed HIV into a manageable, chronic health condition, enabling people living with HIV to lead long and healthy lives. While attitudes and understanding of HIV have evolved, stigma and misinformation remain. That’s why, we won’t stop until we make HIV history.
Through ViiV Healthcare (majority owned by GSK), the world's only company 100% dedicated to preventing, treating and curing HIV, we have been at the forefront of HIV innovation. But we’re not done yet – our scientists are laser focused on developing the next generation of HIV innovations that allow people impacted by HIV to take fewer medicines or take them much less often.
Our HIV partnerships
Our commitment to research and development drives us to continuously explore new avenues. By leveraging our expertise and collaborative partnerships, we aim improve outcomes for those impacted by HIV.
We know there isn’t a ‘one size fits all’ solution to treating, preventing or even curing HIV – that’s why, working hand-in-hand with R&D partners like Shionogi, we’re committed to developing the next-generation of HIV innovation driven by unmet need and unparalleled patient insights.
Alongside our novel approach to R&D, we’re committed to powerful partnerships that drive impact at scale. Key to this is increasing access to medicines and reaching those most impacted by HIV, no matter who they are or where they live. We do this through responsible pricing, sharing intellectual property and cross-sector collaboration working with organisations like International Aids Society, Clinton Health Access Initiative and Medicines Patent Pool. As an example, our voluntary licence agreements allow generic manufacturers to develop paediatric formulations of our medicines where 99% of children living with HIV live.
Across the world, persistent stigma and harmful misinformation threaten to undermine progress. That’s why we work with, partner and invest in the community and key stakeholders to tackle HIV-related challenges and support the most vulnerable. For example, through ViiV’s Positive Action programme, we work directly with grassroot organisations to co-create solutions that strengthen healthcare systems and create healthier communities.
